Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) has been a biopharmaceutical company focused on developing tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, for the frontline treatment of hematologic malignancies. Company news has centered on higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) in patients whose disease exhibits RARA gene overexpression.
News coverage for Syros includes clinical trial updates from key studies such as the Phase 3 SELECT-MDS-1 trial in HR-MDS and the Phase 2 SELECT-AML-1 trial in AML. These announcements have detailed trial designs, interim analyses, complete response (CR) and CRi rates, and decisions to continue or discontinue enrollment based on prespecified futility analyses. Press releases have also discussed the safety profile of tamibarotene in combination regimens and the company’s interpretation of clinical data.
Financial and corporate updates form another important category of news for SYRS. Syros has reported quarterly financial results, described its cash position and operating expense trends, and outlined expectations for how long existing cash and cash equivalents may fund operations. The company has also provided business updates around pre-commercial activities, conference presentations, and webcast events focused on HR-MDS disease biology and the treatment landscape.
More recent news has highlighted material corporate developments, including the failure of the SELECT-MDS-1 trial to meet its primary endpoint, the resulting event of default under Syros’ loan agreement, and the company’s decision to operate as a wind-down. Additional announcements describe the Board’s approval of a voluntary delisting from Nasdaq, plans to deregister the common stock, and the sale of tamibarotene-related clinical and non-clinical assets to Rege Nephro Co., Ltd. Investors and observers can use the SYRS news stream to follow this transition from late-stage clinical development activities to an orderly wind down of operations.
Rege Nephro has acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals (NASDAQ:SYRS) on February 26, 2025. The acquisition includes clinical and non-clinical data, human safety study for NDA, CMO contracts, and Tamibarotene API and drug products.
Tamibarotene (RN-014), a retinoic acid receptor agonist, is currently in Phase 2 clinical trials in Japan for autosomal dominant polycystic kidney disease (ADPKD). Rege Nephro plans to initiate U.S. clinical trials after confirming efficacy and safety in Japan. Previously, Syros conducted Phase 3 trials of Tamibarotene for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Syros Pharmaceuticals (NASDAQ:SYRS) has announced its intention to voluntarily delist from the Nasdaq Stock Market and deregister its common stock. The company plans to file Form 25 with the SEC around March 10, 2025, with delisting expected to take effect near March 20, 2025.
This decision follows multiple Nasdaq compliance issues, including the stock trading below $1.00, falling below the $50 million minimum value requirement, and having market value of publicly held shares below $15 million. The critical factor driving this decision was the failure of the company's SELECT-MDS-1 Phase 3 trial for tamibarotene, which triggered a default under their Oxford Finance loan agreement.
The company will operate under a wind-down budget approved by Oxford Finance, with the Board determining these actions necessary to preserve cash for an orderly wind-down of operations and maximize remaining value for stakeholders.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that its SELECT-MDS-1 Phase 3 trial of tamibarotene combined with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression failed to meet its primary endpoint. The complete response rate in the treatment arm was 23.8% compared to 18.8% in the control arm, which was not statistically significant. The safety profile was generally well-tolerated. The company will discontinue the study and evaluate next steps. The trial failure triggers a default event under Syros' secured loan facility with Oxford Finance
Syros Pharmaceuticals reported Q3 2024 financial results, highlighting zero revenue compared to $3.8M in Q3 2023 due to Pfizer collaboration termination. R&D expenses decreased to $20.5M from $28.3M, while G&A expenses reduced to $5.7M from $7.8M. The company reported a net loss of $6.4M ($0.16 per share) versus $40.1M ($1.43 per share) in Q3 2023. Cash position stands at $58.3M, expected to fund operations into Q3 2025. Pivotal Complete Response data from SELECT-MDS-1 Phase 3 trial for tamibarotene in HR-MDS patients is expected mid-November 2024.
Syros Pharmaceuticals (NASDAQ:SYRS) has scheduled its third quarter 2024 financial results announcement and business update for Thursday, October 31, 2024, at 8:30 a.m. ET. The company will host a live conference call and webcast accessible via phone at (800) 549-8228 (domestic) or (289) 819-1520 (international) using conference ID 07454. A webcast replay will be available for approximately 30 days on the company's website.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced its participation in two upcoming events. At the Society of Hematologic Oncology (SOHO) Annual Meeting from September 4-7 in Houston, Texas, Syros will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial. The presentation, titled 'SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy', is scheduled for September 4, 2024, at 5:15-6:30 PM CT.
Additionally, Syros management will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 11:30 AM ET in New York City. A live webcast of this presentation will be available on the company's website, with an archived replay accessible for approximately 30 days afterward.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespecified interim analysis of 51 patients, which showed similar complete response rates in both arms (65% triplet vs. 70% doublet). No new safety concerns were identified. Syros will present the trial data at the SOHO Annual Meeting in September 2024.
Despite this setback, Syros remains committed to evaluating tamibarotene in combination with azacitidine for higher-risk myelodysplastic syndrome (MDS) in the ongoing SELECT-MDS-1 Phase 3 trial, with pivotal data expected by mid-fourth quarter 2024.
Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Pivotal Complete Response (CR) data from SELECT-MDS-1 Phase 3 trial expected by mid-Q4 2024.
2. Additional data from SELECT-AML-1 Phase 2 trial expected in September 2024.
3. Q2 2024 net loss of $23.3 million, or $0.59 per share, compared to $36.3 million, or $1.30 per share, in Q2 2023.
4. Cash, cash equivalents, and marketable securities of $79.0 million as of June 30, 2024.
5. Current funds expected to support operations into Q3 2025, beyond pivotal Phase 3 data readouts.
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company focusing on hematologic malignancies, has announced its upcoming second quarter 2024 financial results report. The company will host a live conference call and webcast on Wednesday, July 31, 2024, at 8:30 a.m. ET to present the results and provide a business update. Interested parties can access the call via phone or webcast, with details available on the company's website. An archived replay of the webcast will be accessible for approximately 30 days after the call.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a webcast on June 25, 2024, from 11:00 a.m. to 12:30 p.m. ET to discuss higher-risk myelodysplastic syndrome (HR-MDS) and the potential of tamibarotene as a new frontline treatment for patients with RARA gene overexpression. Three medical experts will join Syros’ leadership to provide an overview of patient management, current and future treatment landscapes, and tamibarotene's opportunity. Syros is evaluating tamibarotene in pivotal Phase 3 SELECT-MDS-1 and Phase 2 SELECT-AML-1 trials, with pivotal data expected by mid-Q4 2024 and clinical activity and tolerability data by Q3 2024. The event will include presentations on HR-MDS disease overview, current therapies, trial outcomes, and tamibarotene’s mechanism of action.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
